TearLab Gets FDA Approval for Wider Use of Eye Test

The FDA granted a Clinical Laboratory Improvement Amendments to TearLab to widen the use of its Osmolarity System, a test for dry eye, according to a Reuter’s report.

Advertisement

The change came after the device was reclassified to “simple” instead of “moderately complex”. Previously, an eye practice had to obtain CLIA certification through paperwork and a 20-hour CME course to use the device. Company shares were trading up at much as 80 percent after the announcement.

Related Articles on Ophthalmology:
Thyroid Eye Disease Sufferers Who Smoke More Likely to Need Surgery
Guidelines for Treatment Course of Age-Related Macular Degeneration Updated
BIOLASE Laser Technology Issued Patent to Treat Eye Conditions

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.